ALLN-177: Phase IIb started

Allena began a double-blind, placebo-controlled, crossover, U.S. Phase IIb trial to evaluate 1,500, 3,000 and 7,500 units/meal oral ALLN-177 thrice daily in up to 60 patients. ...